Erasca is a high-risk, binary oncology bet where breakthrough RAS/MAPK science, a large cancer market, and strong cash runway collide with fatal safety signals, patent litigation, and heavy dilution risk.
Overview
Erasca is a pre-revenue clinical-stage precision oncology company targeting the historically difficult RAS/MAPK pathway, altered in roughly 30% of solid tumors. Its pipeline aims to overcome resistance across high-incidence cancers including lung, pancreatic, and colorectal cancer. Lead candidates ERAS-0015 and ERAS-4001 offer potentially differentiated mechanisms, potency, and safety profiles. The opportunity is large, with millions of annual RAS-mutant cancer diagnoses globally, but commercialization remains years away and dependent on clinical success, regulatory approval, intellectual property protection, and future financing.